DDInter596 DDInter1750
Doxorubicin is a cytotoxic anthracycline antibiotic isolated from cultures of Streptomyces peucetius var. caesius along side with daunorubicin, another cytotoxic agent, in 1970.[A1575,A257709,A257614] Although they both have aglyconic and sugar moieties, doxorubicin's side chain terminates with a primary alcohol group compared to the methyl group of daunorubicin. Although its detailed molecular mechanisms have yet to be understood, doxorubicin is generally thought to exert its effect through DNA intercalation, which eventually leads to DNA damage and the generation of reactive oxygen species. Thanks to its efficacy and broad effect, doxorubicin was approved by the FDA in 1974 to treat a variety of cancer, including but not limited to breast, lung, gastric, ovarian, thyroid, non-Hodgkin’s and Hodgkin’s lymphoma, multiple myel
Tazemetostat is a methyltransferase inhibitor used to treat metastatic or locally advanced epithelioid sarcoma not eligible for complete resection. Tazemetostat was first named in literature as EPZ-6438. Tazemetaostat was granted FDA approval on 23 January 2020.
Doxorubicin {u} (Compound) binds {v} (Gene) ABCB1
ABCB1 {u} (Gene) is bound by {v} (Compound) Lidocaine
Lidocaine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Tazemetostat
Doxorubicin {u} (Compound) binds {v} (Gene) ABCB1
ABCB1 {u} (Gene) is bound by {v} (Compound) Bosutinib
Bosutinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Tazemetostat
Doxorubicin {u} (Compound) causes {v} (Side Effect) Nausea
Nausea {u} (Side Effect) is caused by {v} (Compound) Lidocaine
Lidocaine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Tazemetostat
Doxorubicin {u} (Compound) causes {v} (Side Effect) Nausea
Nausea {u} (Side Effect) is caused by {v} (Compound) Bosutinib
Bosutinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Tazemetostat
Doxorubicin {u} (Compound) binds {v} (Gene) CYP2B6
CYP2B6 {u} (Gene) is bound by {v} (Compound) Regorafenib
Regorafenib {u} may lead to a major life threatening interaction when taken with {v} Tazemetostat
Doxorubicin {u} (Compound) causes {v} (Side Effect) Nervousness
Nervousness {u} (Side Effect) is caused by {v} (Compound) Clarithromycin
Clarithromycin {u} may lead to a major life threatening interaction when taken with {v} Tazemetostat
Doxorubicin {u} (Compound) treats {v} (Disease) hematologic cancer
hematologic cancer {u} (Disease) is treated by {v} (Compound) Bortezomib
Bortezomib {u} may cause a minor interaction that can limit clinical effects when taken with {v} Tazemetostat
Doxorubicin {u} (Compound) downregulates {v} (Gene) HSPA8
HSPA8 {u} (Gene) is upregulated by {v} (Compound) Bortezomib
Bortezomib {u} may cause a minor interaction that can limit clinical effects when taken with {v} Tazemetostat
Doxorubicin {u} (Compound) treats {v} (Disease) hematologic cancer
hematologic cancer {u} (Disease) is treated by {v} (Compound) Vinorelbine
Vinorelbine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Tazemetostat
Doxorubicin {u} (Compound) downregulates {v} (Gene) HSPA8
HSPA8 {u} (Gene) is downregulated by {v} (Compound) Irinotecan
Irinotecan {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Tazemetostat
Doxorubicin (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Lidocaine (Compound) and Lidocaine may cause a minor interaction that can limit clinical effects when taken with Tazemetostat
Doxorubicin (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Bosutinib (Compound) and Bosutinib may cause a moderate interaction that could exacerbate diseases when taken with Tazemetostat
Doxorubicin (Compound) causes Nausea (Side Effect) and Nausea (Side Effect) is caused by Lidocaine (Compound) and Lidocaine may cause a minor interaction that can limit clinical effects when taken with Tazemetostat
Doxorubicin (Compound) causes Nausea (Side Effect) and Nausea (Side Effect) is caused by Bosutinib (Compound) and Bosutinib may cause a moderate interaction that could exacerbate diseases when taken with Tazemetostat
Doxorubicin (Compound) binds CYP2B6 (Gene) and CYP2B6 (Gene) is bound by Regorafenib (Compound) and Regorafenib may lead to a major life threatening interaction when taken with Tazemetostat
Doxorubicin (Compound) causes Nervousness (Side Effect) and Nervousness (Side Effect) is caused by Clarithromycin (Compound) and Clarithromycin may lead to a major life threatening interaction when taken with Tazemetostat
Doxorubicin (Compound) treats hematologic cancer (Disease) and hematologic cancer (Disease) is treated by Bortezomib (Compound) and Bortezomib may cause a minor interaction that can limit clinical effects when taken with Tazemetostat
Doxorubicin (Compound) downregulates HSPA8 (Gene) and HSPA8 (Gene) is upregulated by Bortezomib (Compound) and Bortezomib may cause a minor interaction that can limit clinical effects when taken with Tazemetostat
Doxorubicin (Compound) treats hematologic cancer (Disease) and hematologic cancer (Disease) is treated by Vinorelbine (Compound) and Vinorelbine may cause a moderate interaction that could exacerbate diseases when taken with Tazemetostat
Doxorubicin (Compound) downregulates HSPA8 (Gene) and HSPA8 (Gene) is downregulated by Irinotecan (Compound) and Irinotecan may cause a moderate interaction that could exacerbate diseases when taken with Tazemetostat